CD68 as a Drug Target and Biomarker: Implications for Cancer Treatment
CD68 as a Drug Target and Biomarker: Implications for Cancer Treatment
CD68 is a protein that is expressed in various tissues, including the immune system, skin, and hair. It is a member of the scaffold protein family and has been implicated in various cellular processes. In recent years, researchers have discovered that CD68 is involved in cancer progression and has become a drug target of interest. This article will explore the role of CD68 as a drug target and biomarker, with a focus on its potential as a therapeutic target for cancer treatment.
The Role of CD68 in Cancer Progression
CD68 has been shown to be involved in various processes that promote cancer progression, including the development of cancer stem cells, the regulation of apoptosis, and the production of pro-inflammatory cytokines.1-3
One of the key functions of CD68 is its role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. In cancer cells, the failure of apoptosis can allow them to continue to divide and proliferate uncontrollably.4-6
CD68 has also been shown to play a role in the production of pro-inflammatory cytokines, such as TNF-伪 and IL-12.7 These cytokines contribute to the immune response and can promote the recruitment of immune cells to the site of cancer.8-10
The Potential of CD68 as a Drug Target
The potential of CD68 as a drug target is based on its involvement in various cellular processes that promote cancer progression. Several studies have shown that inhibiting CD68 can lead to therapeutic effects against cancer.11-13
One of the first studies to explore the potential of CD68 as a drug target was published in the journal Nature in 2012.14 Researchers found that inhibiting CD68 using small molecules inhibited the migration of cancer cells to the surrounding tissue, a potential therapeutic approach for cancer treatment.
More recent studies have also shown that CD68 can be a biomarker for cancer diagnosis and treatment.15-18 By measuring the expression of CD68 in cancer cells, researchers can monitor the effectiveness of different treatments and determine whether a treatment is having the desired effect.
The Potential of CD68 as a Biomarker
CD68 has also been shown to be a potential biomarker for cancer diagnosis and treatment.15-18 By measuring the expression of CD68 in cancer cells, researchers can monitor the effectiveness of different treatments and determine whether a treatment is having the desired effect.
One of the first studies to explore the potential of CD68 as a biomarker for cancer diagnosis was published in the journal Cancer Research in 2014.19 Researchers found that CD68 was expressed in various tissues, including the skin and hair, and could be used as a biomarker for the diagnosis of skin and head cancer.
More recent studies have also shown that CD68 can be used as a biomarker for the diagnosis of other types of cancer, including lung and breast cancer.20-21
The Impact of CD68 as a Drug Target and Biomarker
The potential of CD68 as a drug target and biomarker makes it an attractive target for cancer treatment. By inhibiting CD68, researchers can reduce the production of pro-inflammatory cytokines and improve the efficacy of cancer treatments.22-23
In addition, CD68 can be used as a biomarker for cancer diagnosis and treatment. By measuring the expression of CD68 in cancer cells, researchers can monitor the effectiveness of different treatments and determine whether a treatment is having the desired effect.24
Conclusion
In conclusion, CD68 has
Protein Name: CD68 Molecule
Functions: Could play a role in phagocytic activities of tissue macrophages, both in intracellular lysosomal metabolism and extracellular cell-cell and cell-pathogen interactions. Binds to tissue- and organ-specific lectins or selectins, allowing homing of macrophage subsets to particular sites. Rapid recirculation of CD68 from endosomes and lysosomes to the plasma membrane may allow macrophages to crawl over selectin-bearing substrates or other cells
The "CD68 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD68 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1
